Table 1.
Patient characteristics (n, %) (N = 320).
| Characteristics | Number (%) |
|---|---|
| Age (years), median (IQR) | 50 (45–58) |
| Body mass index (kg/m2), median (IQR) | 23.8 (21.7–26.2) |
| Body surface area (m2), median (IQR) | 1.6 (1.5–1.7) |
| ER status | |
| Negative | 58 (18.1%) |
| Positive | 262 (81.9%) |
| PR status | |
| Negative | 149 (46.6%) |
| Positive | 171 (53.4%) |
| HER2 status | |
| Negative | 275 (85.9%) |
| Positive | 45 (14.1%) |
| Cancer stage | |
| I | 97 (30.3%) |
| II | 181 (56.6%) |
| III | 42 (13.1%) |
| Comorbidities | |
| Cardiovascular diseases | 54 (16.9%) |
| Diabetes mellitus | 25 (7.8%) |
| Thyroid diseases | 20 (6.3%) |
| Rheumatoid diseases | 3 (0.9%) |
| Menopause status | |
| Pre-menopause | 177 (55.3%) |
| Post-menopause | 143 (44.7%) |
| Use of G-CSF | |
| Secondary prophylaxis | 108 (33.8%) |
| Lipegfilgrastim | 63 (58.3%) |
| Pegfilgrastim | 45 (41.7%) |
| Treatment | 65 (20.3%) |
| None | 147 (45.9%) |
| Basal laboratory values, median (IQR) | |
| WBC count (×103/μL) | 6.2 (5.2–7.2) |
| ANC (cells/mm3) | 3270 (2530–4130) |
| Hemoglobin (g/dL) | 13.1 (12.3–13.7) |
| Platelet count (×103/μL) | 249.0 (218.3–295.0) |
| AST (IU/L) | 24.0 (20.0–28.0) |
| ALT (IU/L) | 17.0 (13.0–24.8) |
ANC, absolute neutrophil count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ER, estrogen receptor; G-CSF, granulocyte colony-stimulating factor; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; PR, progesterone receptor; WBC, white blood cell.